Dalton Pharma Services has declared the signing of a drug development and manufacturing services agreement with Oryn Therapeutics, an American biotechnology firm.
Under the signed agreement, Dalton will provide drug development and cGMP aseptic liquid filling of ORTD-1 in glass vials which will be used for Phase-1 clinical studies of ORTD-1 by the 3rd quarter of this year.
ORTD-1 is a first-in-class drug for treatment of rheumatoid arthritis (RA). RA affects about 1% of the population worldwide. It is the third most common type of arthritis and causes more disability than any other condition, including heart disease, diabetes and back/spine problems. Due to its severely debilitating nature in advanced stages, it accounts for 22% of all deaths from arthritis and other rheumatic conditions. ORTD-1 treatment of experimental arthritis in rats has been shown to induce remission of established disease after only 9 days of treatment. The remission is long lasting (2-3 months) after treatment is discontinued.
“Dalton is privileged to be associated with Oryn in its commitment to develop a safe and effective first-in-class drug treatment for RA”, said Peter Pekos, CEO and President, Dalton Pharma Services.